The LATITUDE UC Study is evaluating the efficacy and safety of an investigational oral treatment for ulcerative colitis (UC). Participants will receive the investigational treatment or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.   

The LATITUDE CD Study is evaluating the efficacy and safety of an investigational oral treatment for Crohn’s disease. Participants will receive the investigational treatment or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures. 

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of investigational      drug in inducing and maintaining clinical remission in pediatric patients 2 to 17 years of age with moderately   to severely active UC, who have had an inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy.

This research study examines the difference in Crohn's disease patient outcomes across several different mobile health applications. This represents the first randomized controlled trial of mobile health applications among Crohn's patients for managing their health and disease symptoms.

The objective of the BOOM-IBD2 clinical trial is to evaluate the effectiveness of an investigational nerve stimulation (neuromodulation) device for ulcerative colitis (UC). This treatment involves implanting a small electronic device that delivers mild electrical pulses to a nerve near the tailbone. The study will assess the impact of this therapy on bowel urgency, quality of life, inflammation, and other measures over a 12-month period through a combination of in-person and virtual visits.

To create a high-risk for inflammatory bowel disease research cohort, by enrolling individuals who have a first-degree relative (parent sibling, or child) with inflammatory bowel disease (IBD; including Crohn’s disease, ulcerative colitis, or IBD unclassified/indeterminate colitis), but who do not have one of these diseases themselves.

To monitor behaviors, diet, and biomarkers of IBD in these unaffected first-degree relatives over time, to better understand how to predict and prevent the development of IBD in high-risk individuals.

To demonstrate the effectiveness of the investigational drug GS-5290, compared to placebo control, in achieving Clinical Response at Week 12

The objective of this study is to assess the PK, efficacy, and safety of the investigational drug in pediatric patients with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to aminosalicylates, oral locally acting corticosteroids, systemic corticosteroids, immunosuppressants, and/or biologic therapies.

To determine the effect of dual targeted therapy with an anti-integrin (VDZ) and a JAK inhibitor (TOF) on clinical remission.